ASGCT Webinar: Maintaining Commercial Cell Therapy Products Chain of Custody

Description:

This webinar was held on Wednesday, February 14, 2018, at 11:00 ET. The recent widespread and commercial use of immune effector cells has led to increased complexity in maintaining chain of custody. In cellular therapy's earliest days, the cell products were managed almost exclusively by the principal investigators themselves. Today, immune effector cells are managed by a team of collection facilities, commercial manufacturers, GMP-compliant laboratories, cell processing facilities, and couriers. Dr. Sarah Nikiforow of the Dana Farber Cancer Institute / Cell Manipulation Core Facility, Dr. Rayne Rouce of the Baylor College of Medicine, Stem Cell Transplant Program, Texas Children's Hospital and Houston Methodist Hospital, and Dr. Solveig Ericson, Executive Director of the CAR-T Program at Novartis Pharmaceuticals Corporation, discussed the importance of maintaining chain of custody for these personalized cellular therapy products, particularly commercialized cell therapy products.